Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.

Gastroenterology - 1 Jun 2009

Chan Andrew T, Zauber Ann G, Hsu Meier, Breazna Aurora, Hunter David J, Rosenstein Rebecca B, Eagle Craig J, Hawk Ernest T, Bertagnolli Monica M

Abstract excerpt

BACKGROUND & AIMS: Variants in the cytochrome P450 2C9 (CYP2C9) gene are associated with impaired metabolism of celecoxib. We examined the influence of CYP2C9*2 (R144C) and CYP2C9*3 (I359L) variants on dose-related response or toxicity in a randomized trial of celecoxib. METHODS: We identified in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoma
Share to Aryl Hydrocarbon Hydroxylases
Share to Confidence Intervals

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Drug Administration Schedule

Share to Probability

Share to Pyrazoles

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 19233181
DOI: 10.1053/j.gastro.2009.02.045
PMCID: PMC2693443

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-19233181-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.PMID 19233181Read ↗

CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment.Semantic proximity Read ↗

A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma.Semantic proximity Read ↗

Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.Semantic proximity Read ↗

No modification of the beneficial effect of NSAIDs on colorectal cancer by CYP2C9 genotype.Semantic proximity Read ↗

Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite.Semantic proximity Read ↗

Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.Semantic proximity Read ↗

Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention.Semantic proximity Read ↗

Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.Semantic proximity Read ↗

The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma.Semantic proximity Read ↗

Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.Semantic proximity Read ↗

Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.Semantic proximity Read ↗

CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.